原発性ER陽性およびHER2陰性乳がんにおける同型再結合欠乏症
Helen R Davies1, Daniella Black1, Anders Kvist2
1Department of Genomic Medicine, School of Clinical Medicine & Early Cancer Institute, University of Cambridge, Cambridge, UK.
Communications medicine
|February 16, 2026
まとめ
ホモログ性再結合欠乏症 (HRD) は,エストロゲン受容体陽性,HER2陰性乳がん (ERpHER2n BC) では,三重陰性乳がんよりも少ない. HRDの状態は,特に化学療法の使用に関して,治療決定に影響を与える可能性があります.
科学分野:
- 腫瘍学 腫瘍学
- ゲノミクスゲノミクスとは
- 分子生物学は分子生物学である.
背景:
- ホモログ性再結合欠乏症 (Homologous recombination deficiency,HRD) は,トリプルネガティブ乳がん (TNBC) の標的となる異常である.
- エストロゲン受容体陽性,HER2陰性乳がん (ERpHER2n BC) のHRDの罹患率と臨床的意義は,ほとんど不明のままである.
研究 の 目的:
- ERpHER2n BCにおけるHRDの流行,遺伝的基盤,および臨床的影響を調査する.
- ERpHER2n BCのHRD特性をTNBCのHRD特性と比較する.
主な方法:
- 人口を代表するスウェーデンのSCAN-B研究から502のERpHER2n腫瘍の分析.
- 全ゲノムシーケンシング (WGS) は,変異シグネチャーに基づくHRDを定義する.
- 対応したトランスクリプション,DNAメチル化,臨床病理学,治療,結果データを統合.
主要な成果:
- HRDは,ERpHER2n BC症例の8.4%で特定され,TNBCよりも著しく低い.
- HRDメカニズムはBRCA1/BRCA2/RAD51C/PALB2不活性化を含み,HRD腫瘍の71.4%を占めています.
- HRD腫瘍は,Luminal Aを除くほとんどのPAM50サブタイプに存在し,明確な転写またはDNAメチル化プロファイルがなかった.
- HRDと,化学療法と内分泌療法を併用した患者のアウトカムとの間に有意な関連性はありません.
- 内分泌療法だけで治療されたHRD腫瘍では,より悪い結果への傾向が観察されました.
結論:
- ERpHER2n HRD腫瘍は,攻撃的な特徴を示していますが,HRに熟練した腫瘍と比較して明確な分子プロファイルがありません.
- 全ゲノムシーケンシング (WGS) ベースのHRD層化は,治療戦略に情報を与える可能性があります.
- 初期の証拠は,HRD BCsが化学療法から利益を得ることができ,化学療法なしでより悪い結果を示すことを示唆しています.
関連する概念動画
Homologous Recombination
63.8K
The basic reaction of homologous recombination (HR) involves two chromatids that contain DNA sequences sharing a significant stretch of identity. One of these sequences uses a strand from another as a template to synthesize DNA in an enzyme-catalyzed reaction. The final product is a novel amalgamation of the two substrates. To ensure an accurate recombination of sequences, HR is restricted to the S and G2 phases of the cell cycle. At these stages, the DNA has been replicated already and the...
63.8K
Homologous Recombination
6.9K
6.9K
Conservative Site-specific Recombination and Phase Variation
6.9K
Because the DNA segments are cut and reorganized in a direction-specific manner, site-specific recombination has emerged as an efficient genetic engineering technique. Flippase and Cyclization recombinases or Flp and Cre, respectively, are two members of the tyrosine recombinase family derived from bacteriophages, that are used to mediate site-specific DNA insertions, deletions, and targeted expression of proteins in mammalian cell lines.
The recognition sites for Cre recombinase called LoxP...
The recognition sites for Cre recombinase called LoxP...
6.9K
Mismatch Repair
6.7K
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
6.7K
Long-patch Base Excision Repair
8.1K
Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:
8.1K
Crossing Over
6.7K
Crossing over is the exchange of genetic information between homologous chromosomes during prophase I of meiosis I. Genetic recombination gives rise to allelic diversity in the newly formed daughter cells. In humans, crossing over produces genetically distinct haploid egg and sperm cells that undergo fertilization to produce unique offspring. Before cell division starts, the germ cell’s chromosome(s) undergo duplication in the S phase of the cell cycle. As the cells enter prophase I,...
6.7K


